MedTrace Logo

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

NCT01580488 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

B LEO 35299 20 mg/g cream

once daily application, 3 weeks

DRUG

C LEO 35299 20 mg/g cream

once daily application, 3 weeks

DRUG

E LEO 35299 10 mg/g solution

once daily application, 3 weeks

DRUG

F LEO 35299 10 mg/g solution

once daily application, 3 weeks

DRUG

Daivonex® ointment

once daily application, 3 weeks

DRUG

Daivonex® ointment vehicle

once daily application, 3 weeks

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Catherine Queille-Roussel, MD · Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière 06202 Nice Cedex 3, France

Study Design

Allocation
NA
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01580488 on ClinicalTrials.gov